Tech Company Financing Transactions
Rheostat Therapeutics Funding Round
On 11/27/2018, Rheostat Therapeutics raised $23 million in Series A funding from AbbVie Biotech Ventures, MRL Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
11/27/2018
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds will be used to advance its programs towards clinical trials, build its internal team and expand studies evaluating biomarkers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA 02101
USA
Boston, MA 02101
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Rheostat's mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Resnick
Chief Scientific Officer
Magdalene Moran
Browse more venture capital transactions:
Prev: 11/27/2018: The High Note venture capital transaction
Next: 11/27/2018: Prose venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs